Calypte Announces Appointment of South African Distributor
Adcock Ingram Scientific Initiates Marketing Activities
PLEASANTON, Calif., July 12 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV) today announced that it has executed a distribution agreement with Adcock Ingram Scientific, based in Johannesburg, South Africa for the marketing and sale of its Aware(TM) rapid HIV antibody tests and HIV Incidence test in South Africa. In conjunction with this agreement, Adcock has placed an order for both the Incidence test and the Aware(TM) OMT rapid test.
"We recently announced the appointment of new distributors for eight countries in sub-Saharan Africa, stated Dr. Richard George, President and CEO of Calypte. Momentum seems to be building, and with the appointment of Adcock in South Africa, we now have qualified representation in eleven sub-Saharan countries. We are delighted that Adcock has placed its initial marketing order for the oral fluid product, which has been commercially available from our Thai contract manufacturing facility since mid-June. This represents our second order for Aware(TM) products in the sub-Saharan region."
Rex Frances, Category Business Executive of the Scientific Division at Adcock, stated, "The Adcock Ingram Critical Care division is proud to be distributing the Calypte range of products in South Africa. Adcock placed its faith in Calypte a long time ago and is delighted to have recently placed its first order for Calypte products. We look forward to a mutually beneficial relationship."
Dr. George concluded by stating that "While it is true that most of the countries in the region are autonomous regarding their approaches to HIV intervention, we believe that the success of Adcock in the South African market will help us drive the adoption of our assays throughout the region."
About Adcock Ingram Scientific:
Adcock Ingram Scientific is a division of Adcock Ingram Critical Care, a wholly owned subsidiary of Tiger Brands. Based in Johannesburg, Tiger Brands is a multinational, multi-billion dollar diversified company with broad interests in healthcare as well as food products and fisheries.
About Calypte Biomedical:
Calypte Biomedical Corporation is a US-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing and commercializing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB/A (No. 2) for the year ended December 31, 2004 and its subsequent filings with the SEC.
Company Contact: Investor Relations Contact:
Richard George, President and CEO Tim Clemensen,
(925) 730-7200 Rubenstein Investor Relations
email:rgeorge@calypte.com Phone: (212) 843-9337
email:tclemensen@rubensteinir.com
SOURCE Calypte Biomedical Corporation
-0- 07/12/2005
/CONTACT: Company Contact: Richard George, President and CEO of Calypte
Biomedical Corporation, +1-925-730-7200, or rgeorge@calypte.com, or Investor
Relations Contact: Tim Clemensen of Rubenstein Investor Relations,
+1-212-843-9337, or tclemensen@rubensteinir.com/
/Web site: http://www.calypte.com/
(HIV)
CO: Calypte Biomedical Corporation; Adcock Ingram Scientific
ST: California, South Africa
IN: HEA MTC BIO
SU:
MC-JS
-- CLM510 --
3958 07/12/2005 10:22 EDT http://www.prnewswire.com
|
Thread abonnieren
